Utilization of Sacubitril/Valsartan in Real-World Settings

被引：0
|
作者：
Efe Eworuke
Talia J. Menzin
Emily C. Welch
Joy Kolonoski
Ting-Ying Huang
机构：
[1] U.S. Food and Drug Administration,Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research
[2] Harvard Medical School and Harvard Pilgrim Health Care Institute,Department of Population Medicine
来源：
American Journal of Cardiovascular Drugs | 2020年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：619 / 623
页数：4
相关论文
共 50 条
  • [21] REAL-WORLD IMPACT OF SACUBITRIL/VALSARTAN ON THE QUALITY OF LIFE OF HEART FAILURE PATIENTS IN PORTUGAL
    Afonso Nogueira, M.
    Afonso-Silva, M.
    Gomes, M.
    Andreozzi, V
    Vandewalle, B.
    Costa Ferreira, F.
    Monica, L.
    Cruz, L.
    Guimaraes, M.
    Proenca, G.
    VALUE IN HEALTH, 2020, 23 : S504 - S505
  • [22] The Real-World Price of Switching to an ARNI A Case for De Novo Sacubitril/Valsartan Initiation
    Page Ii, Robert L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (04) : 332 - 335
  • [23] Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience
    Monzo, Luca
    Ferrari, Ilaria
    Gaudio, Carlo
    Cicogna, Francesco
    Tota, Claudia
    Petronilli, Valentina
    Mennuni, Silvia
    De Ruvo, Ermenegildo
    Calo, Leonardo
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0G)
  • [24] Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience
    Monzo, L.
    Cicogna, F.
    Tota, C.
    Petronilli, V.
    Mennuni, S.
    De Ruvo, E.
    Calo, L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 42 - 43
  • [25] Predictors of Sacubitril-Valsartan target dose achievement in a real-world population.
    Mariana Tinoco, M.
    Cardoso, F.
    Dias, G.
    Pereira, T.
    Faria, B.
    Almeida, F.
    Leite, S.
    Lourenco, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 111 - 111
  • [26] Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience
    Monzo, Luca
    Ferrari, Ilaria
    Gaudio, Carlo
    Cicogna, Francesco
    Tota, Claudia
    Petronilli, Valentina
    Mennuni, Silvia
    Ruvo, Ermenegildo De
    Calo, Leonardo
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL G)
  • [27] Real world experience with sacubitril/valsartan in heart failure
    Lim, E. L. S.
    Abdullah, E. L.
    Loh, L. C. W.
    Chong, P. F.
    Sia, H. P.
    Sothivadivel, S.
    Lee, J. L.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 417
  • [28] SACUBITRIL/VALSARTAN: REAL WORLD EXPERIENCE OF DELIVERY AND TOLERABILITY
    Crawley, Richard
    Guha, Kaushik
    Kalra, Paul
    Morton, Geraint
    HEART, 2017, 103 : A1 - A2
  • [29] SACUBITRIL/VALSARTAN REAL-WORLD PERSISTENCE USING A COHORT OF HEART FAILURE PATIENTS FROM THE PRESCRIPTION & MONITORING OF SACUBITRIL/VALSARTAN STUDY (PRIME 2 STUDY)
    Teixeira Rodrigues, A.
    Murteira, R.
    Bulhosa, C.
    Cary, M.
    Guerreiro, J.
    Laires, P. A.
    Afonso-Silva, M.
    VALUE IN HEALTH, 2020, 23 : S505 - S505
  • [30] The benefits of sacubitril/valsartan in the treatment of patients with heart failure: a real-world, single centre experience
    Celli, Valdisa
    Tari, Ylenia
    Ansani, Katia
    Bernardini, Livio
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N90 - N90
12345